表紙:子宮平滑筋腫 (子宮筋腫)の臨床試験分析(2022年更新版):試験段階、試験状況、試験回数、エンドポイント、ステータス、スポンサータイプ、上位国別
市場調査レポート
商品コード
1111780

子宮平滑筋腫 (子宮筋腫)の臨床試験分析(2022年更新版):試験段階、試験状況、試験回数、エンドポイント、ステータス、スポンサータイプ、上位国別

Uterine Leiomyoma (Uterine Fibroids) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update

出版日: | 発行: GlobalData | ページ情報: 英文 251 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
子宮平滑筋腫 (子宮筋腫)の臨床試験分析(2022年更新版):試験段階、試験状況、試験回数、エンドポイント、ステータス、スポンサータイプ、上位国別
出版日: 2022年06月28日
発行: GlobalData
ページ情報: 英文 251 Pages
納期: 即納可能 即納可能とは
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、子宮平滑筋腫 (子宮筋腫)市場を調査し、地域、国、段階、試験状況、エンドポイント状況、スポンサータイプ別に疾患別の臨床試験情報を提供しています。また、進行中の試験の著名な薬剤も提供しています。

目次

目次

  • レポートガイダンス
  • GlobalData臨床試験調査範囲
  • 地域別の臨床試験
  • 国別の臨床試験と平均登録者数
  • G7諸国別の臨床試験:非悪性疾患に対する子宮平滑筋腫(子宮筋腫)の割合
  • G7諸国における段階別の臨床試験
  • 試験状況別のG7諸国における臨床試験
  • その他

付録

  • 略語
  • 定義
  • 調査手法
  • 2次調査
  • GlobalDataについて
  • カスタマーサービス
  • 情報源
図表

List of Tables

List of Tables

  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials by Region, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Europe, Top Five Countries, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, North America, Top Countries, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2022*
  • Proportion of Uterine Leiomyoma (Uterine Fibroids) to Non-Malignant Disorders Clinical Trials, G7 Countries (%), 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, G7 Countries, Clinical Trials by Phase, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2022*
  • Proportion of Uterine Leiomyoma (Uterine Fibroids) to Non Malignant Disorders Clinical Trials, E7 Countries (%), 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, E7 Countries, Clinical Trials by Phase, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials by Phase, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials In Progress by Phase 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials by Trial Status, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, by End Point Status, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2017-2021
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, Key Sponsors, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2022*

List of Figures

List of Figures

  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials by Region (%), 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, North America, Top Countries (%), 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2022*
  • Proportion of Uterine Leiomyoma (Uterine Fibroids) to Non Malignant Disorders Clinical Trials, G7 Countries (%), 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, G7 Countries, Clinical Trials by Phase, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2022*
  • Proportion of Uterine Leiomyoma (Uterine Fibroids) to Non Malignant Disorders Clinical Trials, E7 Countries (%), 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, E7 Countries, Clinical Trials by Phase, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials by Phase (%), 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials In Progress by Phase, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials by Trial Status, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, by End Point Status, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2017-2021
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, Key Sponsors, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2022*
  • Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2022*
  • GlobalData Methodology
目次
Product Code: GDHC6893CTIDB

GlobalData's clinical trial report, "Uterine Leiomyoma (Uterine Fibroids) - Global Clinical Trials Review, 2022" provides an overview of Uterine Leiomyoma (Uterine Fibroids) Clinical trials scenario. This report provides top line data relating to the clinical trials on Uterine Leiomyoma (Uterine Fibroids). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Clinical Trials by G7 Countries: Proportion of Uterine Leiomyoma (Uterine Fibroids) to Non Malignant Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Uterine Leiomyoma (Uterine Fibroids) to Non Malignant Disorders Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots

Appendix

  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About GlobalData
  • Contact Us
  • Source